Hallucinations

MindMed Adds Psychedelic Assisted Therapy Expert Dr. Peter Gasser As Clinical Advisor For Project Lucy

Retrieved on: 
Thursday, August 6, 2020
Hallucinations, Psychoactive drugs, Counterculture of the 1960s, Entheogens, Lysergic acid diethylamide, RTT, Psychedelic drug, Drugs, Chemical substances

NEW YORK, Aug. 6, 2020 /PRNewswire/ --Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has engaged renowned psychedelic assisted therapy expert Dr. Peter Gasser as an advisor to its LSD experiential therapy program Project Lucy.

Key Points: 
  • NEW YORK, Aug. 6, 2020 /PRNewswire/ --Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has engaged renowned psychedelic assisted therapy expert Dr. Peter Gasser as an advisor to its LSD experiential therapy program Project Lucy.
  • Dr. Gasser has pioneered the legal, medical use of psychedelics through clinical research and compassionate access in Switzerland.
  • Dr. Gasser and University Hospital Basel's Dr Matthias Liechti are conducting a Phase 2 trial of LSD assisted therapy for anxiety disorders.
  • Dr. Gasser helped pioneer compassionate access for end of life psychedelic assisted therapy in Switzerland.

People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights

Retrieved on: 
Wednesday, July 29, 2020
Biotechnology, Health, Philanthropy, Seniors, Pharmaceutical, Mental health, Research, Foundation, Consumer, Science, Clinical trials, Psychiatry, Clinical medicine, Psychopathology, Medical signs, Hallucinations, Abnormal psychology, Psychosis, Auditory hallucination, Delusion, Paraphrenia, Scale for the Assessment of Positive Symptoms, UsAgainstAlzheimer’s, the Lewy Body Dementia Association, ACADIA Pharmaceuticals

View the full release here: https://www.businesswire.com/news/home/20200729005275/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200729005275/en/
    Key findings of the quantitative portion of the survey noted the most common symptoms of dementia-related psychosis reported by patients were visual hallucinations, auditory hallucinations, and distortion of senses.
  • During the qualitative survey, the majority of participants reported that symptoms such as visual hallucinations, auditory hallucinations, and persecutory delusions have an impact on activities of daily living, sleep, family life, and safety concerns.
  • The survey results show that many patients with dementia-related psychosis are unaware of whats happening or how to communicate what they are experiencing.
  • Survey results included the following key findings:
    Of patients who reported recent visual hallucinations, 61 percent indicated they occurred at least weekly.

Filmmaker and Activist Michael "Zappy" Zapolin Calls for Immediate Presidential Executive Order to Legalize Psychedelic Compounds

Retrieved on: 
Wednesday, July 29, 2020
Hallucinations, Psychedelic drug, Hallucinogen

"Nothing else works as effectively or as fast as psychedelic compounds," Zappy explained.

Key Points: 
  • "Nothing else works as effectively or as fast as psychedelic compounds," Zappy explained.
  • "This is a critical moment we're in the middle of a suicide, depression, and PTSD epidemic and a global pandemic.
  • We don't have time to wait before the most healing substances on the planet become available to the masses," said Zappy.
  • "The Mind Army is asking the President of the United States to sign a Presidential Executive Order to make psychedelics legal immediately.

ATAI launches Viridia Life Sciences to develop novel formulations of N, N-Dimethyltryptamine (DMT) for a range of mental health conditions

Retrieved on: 
Wednesday, July 22, 2020
Psychoactive drugs, Entheogens, Hallucinations, Ayahuasca, N,N-Dimethyltryptamine, Psychedelic drug, Indole alkaloid, Hallucinogen

"Our goal is to ensure maximum access to innovative mental health therapies," said Florian Brand, CEO of ATAI.

Key Points: 
  • "Our goal is to ensure maximum access to innovative mental health therapies," said Florian Brand, CEO of ATAI.
  • "DMT represents an opportunity to reach those who might be unable or unwilling to undergo a longer psychedelic experience."
  • DMT is a psychoactive indole alkaloid present in Ayahuasca, a hallucinogenic brew traditionally used in ceremonial settings in South America.
  • Moreover, while DMT is commonly administered intravenously,Viridia is leveraging ATAI Life Science's drug development expertise to generate multiple DMT products based on alternative routes of administration.

Psychedelic Compounds Could be Used in Mental Healthcare

Retrieved on: 
Wednesday, July 15, 2020
Psychiatry, Medicine, Abnormal psychology, Clinical medicine, Psychiatric diagnosis, Cannabis smoking, Hallucinations, Mental disorder, Psychiatric assessment, Drug, Cannabis, Psychedelic drug

Recently, a growing acceptance of psychedelic drugs for treating depression and the increasing prevalence of depression and mental disorders have both become important factors for the market growth of such drugs.

Key Points: 
  • Recently, a growing acceptance of psychedelic drugs for treating depression and the increasing prevalence of depression and mental disorders have both become important factors for the market growth of such drugs.
  • There are similarities between the new psychedelic drugs market and the slightly more mature cannabis market.
  • Such a wide scope of applications is also anticipated to further expand the target demographic of the market.
  • We owe everything to our veterans, EMS and frontline personnel, yet the best solutions for their long-term mental health are currently non-existent.

Psychedelic Compounds Could be Used in Mental Healthcare

Retrieved on: 
Wednesday, July 15, 2020
Psychiatry, Medicine, Abnormal psychology, Clinical medicine, Psychiatric diagnosis, Cannabis smoking, Hallucinations, Mental disorder, Psychiatric assessment, Drug, Cannabis, Psychedelic drug

Recently, a growing acceptance of psychedelic drugs for treating depression and the increasing prevalence of depression and mental disorders have both become important factors for the market growth of such drugs.

Key Points: 
  • Recently, a growing acceptance of psychedelic drugs for treating depression and the increasing prevalence of depression and mental disorders have both become important factors for the market growth of such drugs.
  • There are similarities between the new psychedelic drugs market and the slightly more mature cannabis market.
  • Such a wide scope of applications is also anticipated to further expand the target demographic of the market.
  • We owe everything to our veterans, EMS and frontline personnel, yet the best solutions for their long-term mental health are currently non-existent.

CannaGlobal, Sansero Life Sciences and Rise Wellness Merge to Create a New International Psychedelics Company

Retrieved on: 
Monday, July 6, 2020
Alternative medicine, Pharmaceutical, Health, Mental health, Quality of life, Hallucinations, Positive psychology, Borden Ladner Gervais, Psychedelic drugs, BLG, Well-being, Health, Ladner, Wellness, Articles, Psilocybin

CannaGlobal, Sansero Life Sciences, and Rise Wellness today announced the creation of CannaGlobal Wellness, a global psychedelics leader focused on psilocybin and other natural compounds to promote emotional, mental, and physical wellness.

Key Points: 
  • CannaGlobal, Sansero Life Sciences, and Rise Wellness today announced the creation of CannaGlobal Wellness, a global psychedelics leader focused on psilocybin and other natural compounds to promote emotional, mental, and physical wellness.
  • Leveraging an internationally renowned team with a track record of success, the company will be ideally positioned in the evolving psychedelics industry.
  • Leveraging his vast experience and extensive network in the global cannabis and wellness industries, he founded CannaGlobal to pursue the advancement of cannabis and global wellbeing.
  • Borden Ladner Gervais LLP (BLG) is acting as legal advisor to both Sansero and Rise.

Psychedelic Medicine Stocks Garner Serious Investor Interest

Retrieved on: 
Thursday, June 25, 2020
Hallucinations, Master of Medicine, Psychedelic drug

NEW YORK, June 25, 2020 /PRNewswire/ -- Investor interest in alternative psychedelic medicine is on the rise, with billionaire investors, celebrities, and high-profile execs endorsing the psychedelic medicine market either by joining strategic advisory boards or making sizable investments.

Key Points: 
  • NEW YORK, June 25, 2020 /PRNewswire/ -- Investor interest in alternative psychedelic medicine is on the rise, with billionaire investors, celebrities, and high-profile execs endorsing the psychedelic medicine market either by joining strategic advisory boards or making sizable investments.
  • In fact, there is so much interest in psychedelics medicine that some analysts see the industry bringing in $6.85 billion by 2027 .
  • The sector even experienced the largest-ever private financing round of $80 million for Compass Pathways, a psychedelic medicine company.
  • Among the few publicly-traded psychedelic companies also conducting drug trials and garnering investor interest is Mind Medicine (MindMed) Inc. (MMED) (MMEDF), a neuro-pharmaceutical company that discovers, develops, and deploys psychedelic-inspired medicines to improve health, promote wellness, and alleviate suffering.

Psychedelic Medicine Stocks Garner Serious Investor Interest

Retrieved on: 
Thursday, June 25, 2020
Hallucinations, Master of Medicine, Psychedelic drug

NEW YORK, June 25, 2020 /PRNewswire/ -- Investor interest in alternative psychedelic medicine is on the rise, with billionaire investors, celebrities, and high-profile execs endorsing the psychedelic medicine market either by joining strategic advisory boards or making sizable investments.

Key Points: 
  • NEW YORK, June 25, 2020 /PRNewswire/ -- Investor interest in alternative psychedelic medicine is on the rise, with billionaire investors, celebrities, and high-profile execs endorsing the psychedelic medicine market either by joining strategic advisory boards or making sizable investments.
  • In fact, there is so much interest in psychedelics medicine that some analysts see the industry bringing in $6.85 billion by 2027 .
  • The sector even experienced the largest-ever private financing round of $80 million for Compass Pathways, a psychedelic medicine company.
  • Among the few publicly-traded psychedelic companies also conducting drug trials and garnering investor interest is Mind Medicine (MindMed) Inc. (MMED) (MMEDF), a neuro-pharmaceutical company that discovers, develops, and deploys psychedelic-inspired medicines to improve health, promote wellness, and alleviate suffering.

MindMed Developing IP For Personalized Psychedelic Assisted Therapies

Retrieved on: 
Wednesday, June 24, 2020
Medicine, Articles, Clinical medicine, Hallucinations, Pharmaceutical industry, Psychedelic drug, Medication, Personalized medicine, Mental health

A considerable problem for doctors, clinical researchers, and therapists is to understand and predict optimal doses of psychedelic inspired medicines for patients.

Key Points: 
  • A considerable problem for doctors, clinical researchers, and therapists is to understand and predict optimal doses of psychedelic inspired medicines for patients.
  • MindMed intends to apply this personalized medicine approach to psychedelic assisted therapies for patients suffering from mental health and addiction issues.
  • Healing through psychedelics is a deeply personal process and we believe the personalization of psychedelic therapies is pivotal to the future of this fast growing field of medicine.
  • The MindMed executive team brings extensive biopharmaceutical industry experience to this groundbreaking approach to the development of next-generation psychedelic medicines.